Pharmaceutical

Pint Pharma announces Orladeyo approval in Mexico for HAE prevention

Pint Pharma has announced that COFEPRIS in Mexico has approved ORLADEYO (berotralstat) for the prophylaxis of hereditary angioedema.

May 15, 2024 - 04:00
Pint Pharma announces Orladeyo approval in Mexico for HAE prevention
Pint Pharma has announced that COFEPRIS in Mexico has approved ORLADEYO (berotralstat) for the prophylaxis of hereditary angioedema.
Read the original article

Tags:

Previous Article

UK Government expands opioid overdose treatment access

Next Article

NHS introduces Pfizer’s tafamidis for ATTR-CM treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Brigham and Women’s exec opens up about the Dana-Farber Cancer Institute split, and what it means for the future of cancer care

STAT+: Brigham and Women’s exec opens up about the Dana...

Sep 28, 2023

GLP-1 drugs not linked to suicidal thoughts in FDA’s early review

GLP-1 drugs not linked to suicidal thoughts in FDA’s ea...

Jan 12, 2024

STAT+: Pharmalittle: FDA flags safety concerns with CRISPR-based sickle cell treatment; FDA warns about eye drop infection risk

STAT+: Pharmalittle: FDA flags safety concerns with CRI...

Oct 30, 2023